Stocks of Plus Therapeutics Inc. (NASDAQ:PSTV) traded higher last session on Wall Street, down -53.54% to $1.38.
According to the data, Plus Therapeutics Inc. (NASDAQ:PSTV) has 4 analysts covering its stock. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $32.00 and a low of $8.00, we find $19.00. Given the previous closing price of $2.97, this indicates a potential upside of 539.73 percent. PSTV stock price is now -43.07% away from the 50-day moving average and -67.17% away from the 200-day moving average. The market capitalization of the company currently stands at $8.60M.
A total of 0 analysts have issued a hold rating and 4 have given it a buy rating. Brokers who have rated the stock have averaged $19.50 as their price target over the next twelve months.
With the price target of $8, Ladenburg Thalmann recently initiated with Buy rating for Plus Therapeutics Inc. (NASDAQ: PSTV).
In other news, Clowes Howard, Director bought 1,000 shares of the company’s stock on Jun 06. The stock was bought for $3,980 at an average price of $3.98. Upon completion of the transaction, the Director now directly owns 4,700 shares in the company, valued at $6486.0. An SEC document containing details of the transaction can be found on the SEC’s website. On May 03, Director Clowes Howard bought 2,500 shares of the business’s stock. A total of $9,102 was incurred on buying the stock at an average price of $3.64. This leaves the insider owning 3,700 shares of the company worth $5106.0. Insiders disposed of 1,500 shares of company stock worth roughly $2070.0 over the past 1 year. A total of 0.50% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in PSTV stock. In total, there are 17 active investors with 10.50% ownership of the company’s stock.
Friday’s opening bell rang with an opening price of $3.1600 for Plus Therapeutics Inc. (NASDAQ: PSTV). During the past 12 months, Plus Therapeutics Inc. has had a low of $1.97 and a high of $12.00. As of last week, the company has a debt-to-equity ratio of 1.74, a current ratio of 1.10, and a quick ratio of 1.10. The fifty day moving average price for PSTV is $2.3996 and a two-hundred day moving average price translates $4.1750 for the stock.
The latest earnings results from Plus Therapeutics Inc. (NASDAQ: PSTV) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.59, beating analysts’ expectations of -$1.91 by 1.32. This compares to -$3.56 EPS in the same period last year. For the current quarter, analysts expect PSTV to generate $1.29M in revenue.
Plus Therapeutics Inc.(PSTV) Company Profile
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
